US 11,980,690 B2
Centanafadine pharmaceutical formulations, and methods of making and using same
Syed Asfar Mateen, Robbinsville, NJ (US); Praveen Kumar Mididoddi, Pennington, NJ (US); Shailly Mehrotra, Furlong, PA (US); Susan Elizabeth Shoaf, Silver Spring, MD (US); Salin Gupta, Bridgewater, NJ (US); Kai Suzuki, Osaka (JP); and Masahiro Hasegawa, Osaka (JP)
Assigned to OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed by OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed on Jun. 1, 2023, as Appl. No. 18/204,728.
Application 18/204,728 is a continuation of application No. 18/072,473, filed on Nov. 30, 2022, granted, now 11,759,426.
Application 18/072,473 is a continuation of application No. 17/677,726, filed on Feb. 22, 2022, granted, now 11,564,885, issued on Jan. 31, 2023.
Claims priority of provisional application 63/241,839, filed on Sep. 8, 2021.
Claims priority of provisional application 63/152,826, filed on Feb. 23, 2021.
Prior Publication US 2023/0338293 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/16 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01)
CPC A61K 9/167 (2013.01) [A61K 9/1611 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 31/403 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A pharmaceutical formulation dosage form comprising a plurality of centanafadine beads,
wherein the plurality of centanafadine beads comprise centanafadine or a pharmaceutically acceptable salt thereof and an excipient;
wherein the plurality of centanafadine beads comprises a mixture of a collection of one or more immediate release beads and a collection of one or more sustained release beads,
wherein the centanafadine or a pharmaceutically acceptable salt thereof is present in a greater amount, by weight of the centanafadine or pharmaceutically acceptable salt thereof, in the collection of one or more sustained release beads than in the collection of one or more immediate release beads, and up to a ratio of 1:100 parts by weight of centanafadine or salt thereof, in the collection of one or more immediate release beads to the collection of one or more sustained release beads; and
wherein the dosage form consists of centanafadine or a pharmaceutically acceptable salt thereof as a pharmaceutical active agent.